The MPL mutation is present in 4–5% of JAK2-negative patients, whereas IMF is a complex condition characterized by JAK2 V617F mutation and CALR-gene mutation, in which myeloproliferation often coexists with anemia or thrombocytopenia [5,6,7,8,9]. Here, JAK2 is linked to Thrombocytopenia.